AngioDynamics (NASDAQ:ANGO) Presentation at J.P. Morgan’s 43rd Annual Healthcare Conference

On January 16, 2025, James Clemmer, President and Chief Executive Officer of AngioDynamics, Inc., participated in the J.P. Morgan 43rd Annual Healthcare Conference. During the conference, a presentation was made by James Clemmer, outlining the company’s strategies and future outlook.

The presentation slides included details on AngioDynamics’ expected future financial position, results of operations, business strategy, capital expenditures, and growth opportunities. Highlighting key words such as “expects,” “anticipates,” and “believes,” the presentation comprised forward-looking statements regarding AngioDynamics’ projections.

It is important to note that the information disclosed during this conference, including the presentation slides, shall not be considered as filings pursuant to the Securities Exchange Act of 1934. Additionally, these slides are not to be incorporated by reference into any filings under the Securities Act of 1933 or the Exchange Act.

AngioDynamics, a diversified medical technology company, emphasized its commitment to expanding treatment options and enhancing patient outcomes, focusing on cardiovascular disease and cancer. The presentation emphasized the company’s innovative R&D, clinical and regulatory expansion, and customer-centric sales performance as key pillars of its execution strategy.

The company’s presentation slides also delved into its financial performance, growth projections, market segments, and technology platforms. AngioDynamics highlighted its debt-free status, strong balance sheet, and expectations of achieving positive adjusted EBITDA by fiscal year 2025 and positive cash flow by fiscal year 2026.

Moreover, AngioDynamics referenced various market dynamics, such as the global cardiovascular disease burden and cancer statistics, to underscore its positioning in high-growth markets. The company showcased its differentiated technologies and ongoing investment in research and development to drive sustained growth and profitability in its focus markets.

The presentation slides also covered details on AngioDynamics’ unique technologies, successful portfolio optimizations, clinical and regulatory advancements, and product introductions. The company highlighted its strategic moves, including divestments and revenue projections over the years, aiming for sustainable revenue growth and profit.

This presentation extract encapsulates the key points discussed by AngioDynamics during the J.P. Morgan 43rd Annual Healthcare Conference and provides insights into the company’s strategic direction, growth trajectory, and market positioning.

The official filing and detailed presentation materials can be accessed through the appropriate channels for further information and analysis.

This article is based on the Form 8-K filed by AngioDynamics with the Securities and Exchange Commission on January 16, 2025.

ENDOFFILE

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read AngioDynamics’s 8K filing here.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.